133 related articles for article (PubMed ID: 11100743)
1. Flow-cytometric detection of minimal residual disease with atypical antigen combinations in patients with de novo acute myeloid leukemia.
Plata E; Choremi-Papadopoulou H; Viglis V; Yataganas X
Ann Hematol; 2000 Oct; 79(10):543-6. PubMed ID: 11100743
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease.
Drach J; Drach D; Glassl H; Gattringer C; Huber H
Cytometry; 1992; 13(8):893-901. PubMed ID: 1459006
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
[TBL] [Abstract][Full Text] [Related]
4. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
[TBL] [Abstract][Full Text] [Related]
5. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
[TBL] [Abstract][Full Text] [Related]
8. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of cell marker analysis in de novo acute myeloid leukemia.
Del Poeta G; Stasi R; Venditti A; Suppo G; Aronica G; Bruno A; Masi M; Tabilio A; Papa G
Leukemia; 1994 Mar; 8(3):388-94. PubMed ID: 7907393
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis.
Terstappen LW; Safford M; Könemann S; Loken MR; Zurlutter K; Büchner T; Hiddemann W; Wörmann B
Leukemia; 1992 Jan; 6(1):70-80. PubMed ID: 1540262
[TBL] [Abstract][Full Text] [Related]
11. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
Zelezníková T; Babusíková O
Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
[TBL] [Abstract][Full Text] [Related]
12. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
13. Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings.
Cui W; Zhang D; Cunningham MT; Tilzer L
Int J Lab Hematol; 2014 Dec; 36(6):636-49. PubMed ID: 24602197
[TBL] [Abstract][Full Text] [Related]
14. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
[TBL] [Abstract][Full Text] [Related]
16. [Distribution of antigenic aberration in the bone marrow of acute leukemia in complete remission].
Shin S; Kahng J; Kim M; Lim J; Kim Y; Han K
Korean J Lab Med; 2008 Feb; 28(1):1-7. PubMed ID: 18309249
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease.
Macedo A; Orfao A; Ciudad J; Gonzalez M; Vidriales B; Lopez-Berges MC; Martínez A; Landolfi C; Cañizo C; San Miguel JF
Leukemia; 1995 Nov; 9(11):1896-901. PubMed ID: 7475281
[TBL] [Abstract][Full Text] [Related]
18. [Cellular immunophenotypes in 97 adults with acute leukemia].
Piedras J; López-Karpovitch X; Cárdenas MR
Rev Invest Clin; 1997; 49(6):457-64. PubMed ID: 9528305
[TBL] [Abstract][Full Text] [Related]
19. [Detection of minimal residual disease in patients with acute myeloid leukemia].
Gal'tseva IV; Savchenko VG; Kulikov SM; Parovichnikova EN; Miterev GIu; Maslova ER; Isaev VG
Ter Arkh; 2003; 75(7):8-14. PubMed ID: 12934474
[TBL] [Abstract][Full Text] [Related]
20. Leukemia-associated marker combinations in acute leukemia suitable for detection of minimal residual disease.
Babusíková O; Mesárosová A; Koníková M; Kusenda J; Glasová M; Klobusická M
Neoplasma; 1993; 40(5):275-81. PubMed ID: 8272155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]